Cytotoxic T lymphocyte responses to Epstein-Barr virus

Current Opinion in Immunology

Volumn 8, Issue 4, 1996, Pages 492-497

  Rickinson, Alan B ^a   Lee, Steven P ^a   Steven, Neil M ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; LATENT VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; REVIEW; VIRUS CARCINOGENESIS;

EID: 0030219914     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80036-7     Document Type: Article

References (44)

1. Rickinson AB, Kieff E. Epstein-Barr virus. Fields BN, Knipe DM, Howley PM. Fields Virology. 1996;2397-2446 Lippincott-Raven, Philadelphia.
2. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 176:1992;157-168.
3. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localisation of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 176:1992;169-178.
4. Tamaki H, Beaulieu BL, Somasundaran M, Sullivan JL. Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children. J Infect Dis. 172:1995;739-746.
5. Snudden DK, Smith PR, Lai D, Ng MH, Griffin BE. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene. 10:1995;1545-1552.
6. Wrightham MN, Stewart JP, Janjua NJ, Pepper SDV, Sample C, Rooney CM, Arrand JR. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology. 208:1995;521-530.
7. Walling DM, Perkins AG, Webster-Cyriaque J, Resnick L, Raab-Traub N. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol. 68:1994;7918-7926.
8. Schuster V, Ott G, Seidenspinner S, Kreth HW. Common Epstein-Barr virus (EBV) type 1 variant strains in both malignant and benign EBV-associated disorders. Blood. 87:1996;1579-1585.
9. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol. 75:1994;2729-2740.
10. Stuber G, Dillner J, Modrow S, Wolf H, Szekely L, Klein G, Klein E. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay: low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol. 7:1995;653-663.
11. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. of outstanding interest Nature. 375:1995;685-688 This paper provides strong evidence that EBNA1 is protected from the HLA class I processing pathway, and shows that such protection can be transferred to an otherwise immunogenic protein (EBNA3B) by insertion of the EBNA1 glycine-alanine repeat domain.
12. Khanna R, Burrows SR, Steigerwald-Mullen PM, Thomson SA, Kurilla MG, Moss DJ. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumour surveillance. Virology. 214:1995;633-637.
13. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 67:1993;7428-7435.
14. Lee SP, Thomas WA, Blake NW, Rickinson AB. Transporter (TAP)-independent processing of a multiple membrane spanning protein, the Epstein-Barr virus latent membrane protein 2. of outstanding interest Eur J Immunol. 1996; This paper shows that two CTL epitopes within transmembrane domains of LMP2 are presented in TAP-negative cells, and discusses a novel mechanism whereby such presentation might occur.
15. Biederer T, Volkwein C, Sommer T. Degradation of subunits of the Sec61p complex, an integral component of the ER membrane, by the ubiquitin-proteasome pathway. EMBO J. 15:1996;2069-2076.
16. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBNA3. J Exp Med. 171:1990;345-350.
17. Gavioli R, Kurilla MG, De Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG. Multiple HLA-A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol. 67:1993;1572-1578.
18. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med. 178:1993;879-887.
19. Burrows SR, Gardner J, Khanna R, Stewart T, Moss DJ, Rodda S, Suhrbier A. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol. 75:1994;2489-2493.
20. Hill A, Worth A, Elliott T, Rowland-Jones S, Brooks J, Rickinson A, McMichael AJ. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol. 25:1995;18-24.
21. Hill AB, Lee SP, Haurum JS, Murray N, Yao Q-Y, Rowe M, Signoret N, Rickinson AB, McMichael AJ. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised. of special interest J Exp Med. 181:1995;2221-2228 The first paper to highlight a paradox frequently seen with EBV-epitope-specific CTL clones, namely their inability to lyse the naturally infected autologous LCL target.
22. Lee SP, Morgan S, Skinner J, Thomas WA, Jones SR, Sutton J, Khanna R, Whittle HC, Rickinson AB. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T-lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol. 25:1995;102-110.
23. Levitsky V, Zhang Q-J, Levitskaya J, Masucci MG. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. of outstanding interest J Exp Med. 183:1996;915-926 This paper provides the first evidence to suggest that immunodominance amongst EBV peptide epitopes correlates with their level of representation as peptide-HLA complexes on the LCL cell surface; it also shows that the level of surface representation may not be easily predicted on the basis of work with peptide-HLA complexes in cell-free systems.
24. Argaet VP, Schmidt CW, Burrows SR, Silins SL, Kurilla MG, Doolan DL, Suhrbier A, Moss DJ, Kieff E, Sculley TB, Misko IS. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med. 180:1994;2335-2340.
25. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: Implications for graft versus host disease. J Exp Med. 179:1994;1155-1161.
26. Burrows SR, Silins SL, Moss DJ, Khanna R, Misko IS, Argaet VP. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. of outstanding interest J Exp Med. 182:1995;1703-1715 Following on from [24] and [25], this report shows that HLA-BB-restricted responses to the EBNA3A 325-333 epitope in B8, B44.02-positive individuals involve a different set of TCRs which do not cross-react with B44.02.
27. Parker CP, Gould KG. Influenza A virus: a model for viral antigen presentation to cytotoxic T lymphocytes. Semin Virol. 7:1996;61-73.
28. Nixon DF, McMichael AJ. Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS. 5:1991;1049-1059.
29. + response seen in IM patients is antigen-driven, not induced by a superantigen.
30. + virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology. 219:1996;489-492.
31. + CTL responses to an EBV lytic cycle antigen, BZLF1, involved the reactivation of memory cells by in vitro stimulation with synthetic peptides.
32. + population. Science. 260:1993;98-100.
33. De Campos-Lima P-O, Levitsky V, Brooks J, Lee SP, Hu LF, Rickinson AB, Masucci MG. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med. 179:1994;1297-1305.
34. Burrows JM, Burrows SR, Pulsen LM, Sculley TB, Moss DJ, Khanna R. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. of special interest J Virol. 70:1996;2490-2496 Evidence which, in contrast to [32], implies that mutations in A11-restricted CTL epitopes may be a coincidental feature of SE Asian virus isolates and not the specific result of immune selection.
35. Papadopoulos EB, Ladanyi M, Emmanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Melaspina H, Childs BH, Gillio AP, Small TN, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 330:1994;1185-1191.
36. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. of outstanding interest Lancet. 345:1995;9-13 This report describes the first clinical use of in vitro reactivated EBV-specific CTL preparations and demonstrates their ability not only to reverse the development of EBV-positive lymphoproliferative lesions but also, when used prophylactically, to reduce viral loads in the B-cell pool.
37. Heslop HE, Ng CYC, Li C, Smith CA, Koftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 2:1996;551-555.
38. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regression of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 ScidScid mice. J Exp Med. 183:1996;1215-1228.
39. Khanna R, Burrows SR, Argaet V, Moss DJ. Endoplasmic reticulum signal sequence faciliated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol. 6:1994;639-645.
40. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein 1: co-ordinate up-regulation of peptide transporters and HLA-class I antigen expression. of outstanding interest Eur J Immunol. 25:1995;1374-1384 The impaired antigen-presenting function of BL cells is shown to be associated with downregulation of the TAP1/TAP2 heterodimer and with reduced levels of HLA class I expression; LMP1 gene transfection can reverse these effects and restore antigen processing function.
41. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, Baak JPA, Kluin Ph M, Van der Valk P, Walboomers JMM, Meijer CJLM. Analysis of MHC class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus positive and negative Hodgkin's disease. Blood. 87:1996;3844-3851.
42. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 86:1995;1493-1501.
43. Thomson SA, Khanna R, Gardner J, Burrows SR, Coupar B, Moss DJ, Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein and processed and presented to CD8(+) cytotoxic T-cells - implications for vaccine design. of special interest Proc Natl Acad Sci USA. 92:1995;5845-5849 A very interesting strategy for vaccine design involving the serial linkage of CTL epitope sequences into a single polypeptide expressed from a recombinant viral vector.
44. Morgan SM, Wilkinson GWG, Floettmann E, Blake N, Rickinson AB. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. J Virol. 70:1996;2394-2402.